Across TCGA pan-cancer cohorts, TRAV8-2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAV8-2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TRAV8-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAV8-2 expression acts as an unfavorable survival marker.

OV, LGG, and SARC are the cancer types where TRAV8-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.193	0.541	.013	18	view →
LGG	OS	Median	All	0.177	0.909	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRAV8-2 tumor-vs-normal RNA expression · all TRAV8-2 data types